Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines

Year to date, shares of Beam Therapeutics have lost 5.8% compared with the industry's decline of 2.7%. As part of the leadership transition process, the company is now looking for a new CFO. Terry-Ann Burrell has been an integral part of BEAM's evolution into a leading gene editing company aimed at developing precision genetic medicines through base editing. Image Source: Zacks Investment Research Dosing and engraftment for the three patients in the sentinel cohort of the BEACON study have been completed. D ...